Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Grace Therapeutics, Inc. (GRCE)

$2.33 -0.85% NASDAQ: GRCE · 15-min delayed
  • PRINCETON, New Jersey
  • Public · NASDAQ: GRCE
  • 6 employees
$35.6MMarket cap
$100.0MRevenue · FY2022
-$9.6MNet income
6Employees
GRCENASDAQ
2011IPO

About Grace Therapeutics, Inc.

Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2022
$100.0M
Net income
-$9.6M
Total assets
$72.0M
Market cap
$35.6M

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2026

Financial statements

Income statement

Operating income
-$11.1M
Income tax
-$1.7M
Net income
-$7.8M
EPS (basic)
$-0.47
EPS (diluted)
$-0.47

Balance sheet

Total assets
$66.7M
Current assets
$17.4M
Total liabilities
$2.8M
Current liabilities
$2.1M
Shareholders’ equity
$63.9M

Cash flow

Operating cash flow
-$8.9M
Investing cash flow
$5.2M
Financing cash flow
$3.7M
Net cash flow
$0

Statements via Polygon.io (SEC filings)

NASDAQ: GRCE
$2.33 -0.85%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$2.10 $5.13

52-week range

Market cap
$35.6M
EPS (diluted)
$-0.47
Shares outstanding
15.3M
Open
Day range
Prev close
Volume
IPO date
Apr 26, 2011

Grace Therapeutics, Inc. (GRCE) Stock Price

  • Reported a net loss of $9.6M in FY2022.
  • Trading 55% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Grace Therapeutics, Inc..

Write a review
Newsroom

News about Grace Therapeutics, Inc.

News & sentiment via Polygon.io

FAQ

Grace Therapeutics, Inc.: frequently asked questions

Is Grace Therapeutics, Inc. an American company?

Grace Therapeutics, Inc. is a US-based company headquartered in Princeton, New Jersey, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Grace Therapeutics, Inc. headquartered?

Grace Therapeutics, Inc. is headquartered in Princeton, New Jersey, United States.

Is Grace Therapeutics, Inc. publicly traded?

Yes — Grace Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol GRCE on the NASDAQ.

What does Grace Therapeutics, Inc. do?

Grace Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →